EVMN

Evommune, Inc.

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

6Trials in this database

15Recorded changes · last 12 months

Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source

Trial	Sponsor	Phase	Status	Primary completion
Safety and Efficacy Study of EVO101 Topical Cream in Atopic DermatitisNCT05579899	EVMN	Phase 2	Completed	2023-07-27Actual
A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible UrticariaNCT06603220	EVMN	Phase 2	Completed	2025-05-08Actual
Efficacy Study of EVO301 in Moderate to Severe Atopic DermatitisNCT06723405	EVMN	Phase 2	Completed	2025-11-17Actual
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)NCT06873516	EVMN	Phase 2	Completed	2026-05-29Actual
Phase 2b Study of EVO756 in Adults With Atopic DermatitisNCT07150845	EVMN	Phase 2	Active not recruiting	2026-07Estimated
Study of EVO756 in Adults With MigraineNCT07616128	EVMN	Phase 2	Recruiting	2027-10Estimated

Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis

EVMNCompletedPrimary completion: 2023-07-27 · Actual

Trial details

Registry ID: NCT05579899
Phase: Phase 2

A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria

EVMNCompletedPrimary completion: 2025-05-08 · Actual

Trial details

Registry ID: NCT06603220
Phase: Phase 2

Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis

EVMNCompletedPrimary completion: 2025-11-17 · Actual

Trial details

Registry ID: NCT06723405
Phase: Phase 2

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

EVMNCompletedPrimary completion: 2026-05-29 · Actual

Trial details

Registry ID: NCT06873516
Phase: Phase 2

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

EVMNActive not recruitingPrimary completion: 2026-07 · Estimated

Trial details

Registry ID: NCT07150845
Phase: Phase 2

Study of EVO756 in Adults With Migraine

EVMNRecruitingPrimary completion: 2027-10 · Estimated

Trial details

Registry ID: NCT07616128
Phase: Phase 2

Latest recorded trial changes

Study of EVO756 in Adults With Migraine

NCT07616128 · Evommune, Inc.

Posted 2026-07-01 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

NCT06873516 · Evommune, Inc.

Posted 2026-07-01 · 5 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~160 participants (planned)~~

+ After

182 participants (actual)

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~Jun 2026~~

+ After

29 May 2026

Recruitment status changed

− Before

~~Active not recruiting~~

+ After

Completed

Check registry source

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

NCT07150845 · Evommune, Inc.

Posted 2026-05-18 · 1 field changed

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

NCT06873516 · Evommune, Inc.

Posted 2026-05-11 · 1 field changed

Primary completion date changed

− Before

~~May 2026~~

+ After

Jun 2026

Check registry source

A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria

NCT06603220 · Evommune, Inc.

Posted 2026-04-16 · 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: Safety and ~~tolerability~~

+ After

Measure: Safety and Tolerability

Check registry source

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

NCT06873516 · Evommune, Inc.

Posted 2026-04-09 · 1 field changed

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis

NCT06723405 · Evommune, Inc.

Posted 2025-12-04 · 5 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~60 participants (planned)~~

+ After

71 participants (actual)

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~Nov 2025~~

+ After

17 Nov 2025

Recruitment status changed

− Before

~~Active not recruiting~~

+ After

Completed

Check registry source